There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Amarin (AMRN), Aileron Therapeutics Inc (ALRN) and Durect Corp (DRRX) with bullish sentiments.
H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Amarin today and set a price target of $51. The company’s shares closed on Friday at $20.76, close to its 52-week high of $23.34.
“Our PT of $51 is based on equally weighted average of: (a) $41.37/share, as a 25x multiple of taxed and diluted FY29 GAAP EPS of $6.69 discounted back to and (b) an NPV of $60.99/share (discount rate 10%, growth rate 2%). Risks to our investment thesis and target price include: (1) Vascepa commercial ramp-up and/or peak sales not meeting our projections; and (2) further competitive disruption of the omega-3 market by branded drugs or generics and/ or OTC supplements beyond our model.”
According to TipRanks.com, Fein is a 5-star analyst with an average return of 8.9% and a 47.6% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.
Amarin has an analyst consensus of Strong Buy, with a price target consensus of $32.75, a 57.8% upside from current levels. In a report issued on March 21, Stifel Nicolaus also initiated coverage with a Buy rating on the stock with a $27 price target.
See today’s analyst top recommended stocks >>
Aileron Therapeutics Inc (ALRN)
H.C. Wainwright analyst Edward White maintained a Buy rating on Aileron Therapeutics Inc today and set a price target of $5. The company’s shares closed on Friday at $1.95.
“We are revising our FY19 EPS estimate to ($1.09) from ($1.79). The company reported ending 2018 with $21.3M in cash and equivalents. Following the secondary offering discussed below, management believes the company has a cash runway into December 2020.”
According to TipRanks.com, White is a 4-star analyst with an average return of 8.6% and a 47.4% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Synthetic Biologics Inc.
Currently, the analyst consensus on Aileron Therapeutics Inc is a Moderate Buy with an average price target of $7.
Durect Corp (DRRX)
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Durect Corp, with a price target of $3. The company’s shares closed on Friday at $0.63, close to its 52-week low of $0.46.
“Effective solution to plaque psoriasis is long overdue. 29, DURECT hosted a key opinion leader (KOL) webcast to discuss the plaque psoriasis landscape and a new Phase 2a proof-of-concept (POC) study of topical DUR-928, DURECT’s novel epigenetic regulator, for the treatment of mild to moderate plaque psoriasis. Dr. Howard Maibach is a professor with the Francisco (UCSF), who founded the Psoriasis Clinic at UCSF and previously served as a member of the NDA review board of the FDA. Dr. Maibach outlined the clinical challenges that are faced by clinicians in treating plaque psoriasis, and described the chronic autoimmune condition as largely under-treated due to the lack of effective treatment.”
According to TipRanks.com, Arce is a 4-star analyst with an average return of 6.6% and a 41.9% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Melinta Therapeutics Inc, and Collegium Pharmaceutical.
Durect Corp has an analyst consensus of Moderate Buy, with a price target consensus of $3.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.